Lucira Health to Participate in William Blair 41st Annual Growth Stock Conference
Lucira Health (NASDAQ: LHDX), a leader in innovative infectious disease testing, will participate in the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 10:40 a.m. PT / 1:40 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucira Health (NASDAQ: LHDX), a leader in innovative infectious disease testing, will participate in the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 10:40 a.m. PT / 1:40 p.m. ET. The event can be accessed via a live and archived webcast on their official investor relations site.
Lucira specializes in creating consumer-friendly, lab-quality molecular testing kits, including the LUCIRA COVID-19 All-In-One Test Kit, which delivers results in just 30 minutes.
Details
News Market Reaction – LHDX
The recorded move for LHDX in the trading session of this news was -3.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will be participating in the William Blair 41st Annual Growth Stock Conference.
Lucira Health’s management is scheduled to participate in the conference on Wednesday, June 2, 2021, at 10:40 a.m. PT / 1:40 p.m. ET. Interested parties can access the live and archived webcast at ir.lucirahealth.com.
About Lucira Health
Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira’s testing platform produces lab quality molecular testing in a single-use, consumer-friendly, palm size test kit powered by two AA batteries. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular tests results anywhere and anytime. The LUCIRA CHECK IT (OTC) and LUCIRA COVID-19 All-In-One (RX) Test Kits are designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. For more information, visit www.lucirahealth.com.
Investor Contact
Greg Chodaczek
Investorrelations@lucirahealth.com
347-620-7010
Media Contact
Kevin Knight
media@lucirahealth.com
206-451-4823
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.